ChiCTR2200058323
Untitled Trial
Single-arm ,an open-label, single-center?clinical study of microwave ablation combined with Tirelizumab and Fruquintinib for the treatment of as third-line chemotherapy in patients with advanced colorectal cancer
Zhongshan Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine·Not Applicable·Chinese Clinical Trial RegistryNot yet recruiting
View on Chinese Clinical Trial Registry →Study focus
- Disease/Condition
- colorectal cancer
- Drug/Device/Intervention
- Tirelizumab: 200mg, given intravenously on the first day of each cycle, once every three weeks, for continuous administration until disease progression, intolerance to toxicity, or voluntary withdrawal of informed consent. Furoqueitinib: 5mg orally, once daily for 2 weeks, stopped for 1 week, every 3 weeks, continuously administered until the subject develops disease progression, intolerance to toxicity, or voluntary withdrawal of informed consent. Microwave ablation: the microwave power was 120W, the temperature was (90±10) ℃, and the ablation lasted for 8-11 minutes. The ablation range was expanded 1~2cm outward from the lesion.
Sponsor & location
- Primary sponsor
- Zhongshan Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine
- Funder
- Self financing
- Location
- China
Timeline & enrollment
- Phase
- Not Applicable
- Start date
- N/A
- End date
- Mar 31, 2024
ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
- Registry
- Chinese Clinical Trial Registry
- Trial ID
- ChiCTR2200058323
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for ChiCTR2200058323 through Pure Global AI's free database. This Not Applicable trial is sponsored by Zhongshan Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine and is currently Not yet recruiting. The study focuses on colorectal cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.